Scarlet Therapeutics, a Bristol, UK-based provider of red blood cell-based therapeutics, raised an undisclosed amount in Seed funding.
The round saw participation from Science Creates Ventures and Meltwind.
The company intends to use the funds to advance development of its platform and build a pipeline of novel therapies to treat rare diseases.
Founded by blood scientists Professor Ash Toye and Professor Jan Frayne and led by CEO Alistair Irvine, Scarlet Therapeutics is developing a platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has a commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.
FinSMEs
23/05/2023